Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 4/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 7/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022272 | 1.00 | UCHL1 (0.49) | UCHL1NOTUMHDAC1HDAC6KDM1A | |
| SCHEMBL3502782 | 0.92 | UCHL1 (0.45) | UCHL1NOTUMHDAC1HDAC6KDM1A | |
| SCHEMBL12068031 | 0.88 | UCHL1 (0.51) | UCHL1NOTUMHDAC1HDAC6KDM1A | |
| SCHEMBL30376147 | 0.88 | UCHL1 (0.48) | UCHL1NOTUMHDAC1HDAC6KDM1A | |
| SCHEMBL2023466 | 0.88 | UCHL1 (0.48) | UCHL1NOTUMHDAC1HDAC6KDM1A | |
| SCHEMBL30681484 | 0.87 | UCHL1 (0.47) | UCHL1NOTUMHDAC1HDAC6KDM1A | |
| SCHEMBL27439537 | 0.86 | UCHL1 (0.47) | UCHL1NOTUMHDAC1HDAC6KDM1A | |
| SCHEMBL30955242 | 0.84 | UCHL1 (0.45) | UCHL1NOTUMHDAC1HDAC6KDM1A | |
| SCHEMBL27439549 | 0.84 | UCHL1 (0.45) | UCHL1NOTUMHDAC1HDAC6KDM1A | |
| SCHEMBL31173330 | 0.83 | HDAC1 (0.46) | UCHL1NOTUMHDAC1HDAC6KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638441-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| EP-4426681-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024133499-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| CN-108137542-B | Pyridone dicarboxamides as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023079294-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-05-11 | — | — | WO | disclosed |
| EP-3262053-B1 | IMIDAZOTHIADIAZOLE COMPOUNDS AS PAR4-INHIBITORS | UNIV MONTREAL (CA) | 2022-10-05 | — | — | EP | disclosed |